Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).

Preguntar a la IA

Me gusta

Guardar

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Bardia et al. (Wed,) studied this question.

synapsesocial.com/papers/69d78dca5f9a1dad534907e8 https://doi.org/https://doi.org/10.1056/nejmoa1814213

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

2012 · 2,798 citations